FDA Decision on Regeneron’s Linvoseltamab Held Back by Third-Party Manufacturer

Regeneron Pharmaceuticals has confirmed that the FDA will not make a decision on approving its investigational multiple myeloma drug linvoseltamab for at least the next few months, citing problems encountered during the preapproval inspection of a contract manufacturer.
Source: Drug Industry Daily